Please assess the completion status of the following clinical trial:

Trial Title: Study of Trans Sodium Crocetinate in Patients With Interstitial Lung Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or Female, age 30 to 85 years at screening~2. Able to provide informed consent and agree to adhere to all study visits and requirements~3. Females of childbearing potential must have a negative blood pregnancy test at screening and agree to use one of the accepted contraceptive regimens, or a double method of birth control during the study and at least 30 days after the last dose of study drug~4. Established diagnosis of ILD (clinical, radiographic, or histologic)~5. SpO2 ≥ 88% at rest by pulse oximetry while breathing ambient air~6. Free of any active cardiovascular or neuromuscular disease, at PI discretion~7. Clinically stable disease with no major medication changes in the last 4 weeks~8. Forced vital capacity (FVC) ≥ 45% of predicted (within past 6 months)~9. DLCO corrected for hemoglobin 30-90% of predicted, inclusive (within past 6 months)~10. Sars-CoV-2 negative at screening~Exclusion Criteria:~1. Known allergy to study medication~2. Pregnancy or lactation~3. Current smoker~4. Inability to perform pulmonary function testing~5. Active infection at screening or day of study visit~6. Known pulmonary hypertension (PH) requiring PH-specific treatment~7. AST/ALT ≥ 3x ULN and/or total bilirubin ≥ 2x ULN~8. Received any investigational medicine (IMP) within past 30 days~9. Surgery or hospitalization in past 3 months determined by the PI to be clinically relevant.~10. Current alcohol or substance abuse~11. Known active or latent hepatitis B or C~12. History of end-stage liver or renal disease~13. Positive COVID test anytime within 3 months of screening. Note:~    Patients who were previously vaccinated for COVID are allowed~14. History of venous thromboembolic disease~15. History of acute or chronic ophthalmologic conditions currently requiring treatment

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 2.5 mg/kg Trans Sodium Crocetinate (Type: EXPERIMENTAL): Subjects will receive a single IV bolus dose of 2.5 mg/kg TSC.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will receive a single IV bolus dose of 7 mL Normal Saline.

Based on this trial design, predict the completion outcome and termination type (if applicable).